Drug Profile
SIWA 318
Alternative Names: SIWA 318H; SIWA318Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator SIWA Therapeutics
- Class Antibacterials; Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bacterial infections; COVID 2019 infections; Influenza A virus infections; Pancreatic cancer
- No development reported Cancer; Muscular dystrophies
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 14 Mar 2022 Pharmacodynamics and adverse events data from a preclinical study in Pancreatic cancer released by SIWA Therapeutics
- 07 Mar 2022 SIWA 318 is still in preclinical trials for Cancer in US